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Introduction
Atrial fibrillation (AF) is the most commonly observed 
arrhythmia in the clinic, and it is associated with complica-
tions such as stroke, heart failure (HF), and sudden death.1 
Recent studies indicate that more than ∼33 million people are 
affected by AF worldwide,2 and this number is expected to 
grow as the general population ages. The incidence of HF is 
also growing alarmingly worldwide, and AF can be both a 
cause and a consequence of HF, which in part substantially 
complicates treatment efforts when both comorbidities coexist.3 
The likelihood of AF is also seen to increase with the sever-
ity of HF, ranging from ∼10% in HF patients classified under 
New York Heart Association (NYHA) Class I, to ∼50% in 
those classified with NYHA Class IV symptoms.3 Even 
though the ionic and structural remodeling that underlies the 
now-classically established paradigm of “AF begets AF”4 is 
fairly well understood,5 the same cannot be said regarding 
how AF is initiated and sustained in the context of HF. It is 
important to understand the underlying mechanisms because 
AF in HF patients is associated with increased mortality and 
morbidity.1 The pathophysiological mechanisms underlying 
the development of AF in HF are multifactorial and complex, 
in addition to involving changes in electrical properties, 
structural modifications, neurohormonal alterations, and 
activation of inflammatory as well as oxidative stress path-
ways.1,3 In this review article, we mainly focus on our current 
understanding of the atrial electrophysiological remodeling 
occurring in HF and how it can lead to sustained arrhyth-
mias. Most of the available insights regarding the ionic and 
molecular mechanisms of atrial electrophysiological changes 
have been primarily obtained via experimental studies using 
animal models of HF, even though substantial gaps remain.6 
We begin by examining the data obtained regarding elec-
trophysiological remodeling occurring in the human atrium 
during left ventricular (LV) dysfunction or HF.
Altered Atrial Electrophysiological Substrate  
in Humans with Ventricular Dysfunction
Sanders et al examined the atrial electrophysiological pro-
perties in patients with severely reduced LV ejection fraction 
(LVEF ∼25%), and their in vivo studies showed that compared 
to age-matched controls, patients in the HF group demonstrated 
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an increased atrial effective refractory period (ERP) in the low 
lateral right atrium and distal coronary sinus, but no change 
in the heterogeneity of ERP.7 Further, in the same study, 
electroanatomical mapping data showed regional slowing 
of impulse propagation, as well as a greater instance of frac-
tionated electrograms (indicative of fibrosis).7 Inducibility of 
AF in patients with HF was increased, as was the duration of 
sustained AF.7 Fedorov et al showed, by optical voltage map-
ping in human coronary-perfused atrial–ventricular free wall 
preparations, that atrial action potential duration (APD) and 
functional refractory period were longer in failing hearts than 
in nonfailing hearts.8 Increased atrial fibrosis has also been 
associated with reduced LVEF in patients.9 Xu et al provided 
evidence for atrial extracellular matrix remodeling in explanted 
hearts of patients with dilated cardiomyopathy and end-stage 
HF.10 The protein level of the tissue inhibitor of metallopro-
teinase (TIMP-2) was downregulated, whereas that of matrix 
metalloproteinase (MMP-2) was upregulated in patients with 
permanent and/or persistent AF, compared to the levels in the 
donor left atrium.10 Cellular studies have also been conducted 
to examine the ionic basis of atrial electro physiological remod-
eling due to HF in humans, and these have provided varied 
results. Koumi et al found that the APD at 90% repolarization 
(APD90) was longer, the resting membrane potential (Vrest) was 
more depolarized, and the plateau phase amplitude was smaller 
in myocytes isolated from the right atrial appendage from HF 
patients (median age: 50 years), compared to controls (median 
age: 38 years).11 These investigators found reduced single-chan-
nel densities for both the inward rectifier K+ current IK1 and 
the acetycholine (Ach)-activated K+ current IKACh, in addition 
to a reduced sensitivity to activation by ACh in the latter, in 
HF tissues, compared to control hearts.11 However, the mean 
open life times and single-channel slope conductance of these 
two currents were similar in HF and control samples.11 It must 
be noted, however, that in the study conducted by Koumi et al 
in 1994, out of 30 HF patients, six were in chronic AF, four 
in paroxysmal AF, and the remaining were in sinus rhythm.11 
In contrast, when Schreieck et al investigated the electrical 
properties of atrial cells obtained from patients with normal 
LVEF (.60% as criterion; mean age: 31 years; lateral left atrial 
wall as source of cells) and reduced LVEF (,45% as criterion, 
mean age: 65 years; right atrial appendage as source), they 
did not find any significant difference in either APD90 or Vrest 
between groups, but the plateau level of atrial action potentials 
in HF was lower, compared to controls.12 These investigators 
excluded not only all patients with AF but also those with a left 
or right atrial enlargement .45 mm. When they investigated 
the underlying ionic mechanisms, they found increased den-
sity of the Ca2+-independent transient outward K+ current, Ito1, 
in human atrial myocytes of patients with reduced LV func-
tion, no change in its voltage dependence or decay, but faster 
recovery from inactivation.12 There was reportedly no differ-
ence in the density of the background or sustained K+ currents; 
the latter is primarily composed of the atrial-specific ultra-
rapid delayed rectifier current, IKur.13 However, it was not clear 
whether the use of beta-blockers was a criterion for the exclu-
sion of patients in this study12; this is important, because such 
a treatment is associated with decreased density of Ito1 in the 
human atrium.14 The most recent investigation was conducted 
by Workman et al.15, whose findings were again different from 
those of previous reports. In atrial cells isolated from patients 
in sinus rhythm (right atrial appendage) with a reduced LVEF 
(,45%), APD90 was shorter than in patients with higher EF, 
although, intriguingly, there was a small increase in the maxi-
mum upstroke velocity of the action potential (Vmax), but no 
change in Vrest.15 There was also a significant positive correla-
tion between LVEF and the atrial cellular ERP; lower LVEFs 
were associated with shorter ERPs. Patch clamp studies showed 
that there were no differences in the densities of IK1, IKur, or the 
L-type Ca2+ current, ICaL.15 However, the density of Ito1 was 
reduced by ∼34% and there was a positive shift in its activation 
voltage in patients with LV systolic dysfunction (LVSD), com-
pared to those with no LVSD.15 This reduction in Ito1 was also 
observed when patients were subanalyzed by treatment with 
beta-blockers.15 It is noteworthy that Ito1 reduction in human 
atrial cells should be expected to increase, rather than decrease, 
APD90,16 and the ion current mechanisms that account for the 
APD shortening in patients with LVSD remain elusive. Atrial 
dilatation is seen commonly in the course of cardiac failure.3 In 
trabeculae and myocytes taken from dilated atria, APD90 was 
shorter and the plateau was markedly depressed compared to 
trabeculae and myocytes from nondilated atria.17 However, it 
must be noted that the ventricular dysfunction was not quanti-
fied in these patients. Action potential changes were explained 
with more severely depressed ICaL compared to the reduction 
in total outward current.17 However, absence of change in ICaL 
has also been reported in atrial cells obtained from explanted 
hearts with dilated atrial appendages,18 while Dinanian et al 
have shown that decreased ICaL was associated with reduced LV 
function and mitral valve disease.19 Thus, overall, there is a lot 
of discrepancy, particularly among the various cellular studies 
characterizing atrial ionic and action potential remodeling 
in human HF, which could be related to cell damage during 
isolation, varied characteristics of patients and/or their exclu-
sion criteria, or experimental conditions (temperature, record-
ing solutions, and so on). Finally, recent studies indicate an 
emerging difference in the atrial dysfunction in HF patients, 
classified as with either preserved or reduced EF; the former 
group was seen to be associated with increased left atrial stiff-
ness and burden of AF, in contrast to the increased dilatation 
and eccentric remodeling seen in the latter.20 However, the 
precise electrostructural determinants of this pathophysio-
logical remodeling and their role in precipitating AF 
remain unclear.
Atrial remodeling in Animal Models of HF
The atrial electrical remodeling occurring due to ventricular 
dysfunction has been studied extensively in animal models 
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(mainly tachypacing-induced or myocardial infarction (MI)-
induced HF).5 In atria of dogs with short-term (three–six 
weeks) ventricular tachypacing-induced HF, the inducibility 
and duration of sustained AF21 or atrial tachycardia (AT)22 
were substantially enhanced. Focal activations were commonly 
seen in both canine and ovine HF models, originating near 
the crista terminalis,23 pulmonary vein regions,23–25 or vein of 
Marshall.25 In atrial recordings from whole hearts, the ERP 
was either increased (three weeks of ventricular tachypacing)22 
or unchanged (five weeks of ventricular tachypacing); in the 
latter case, although there was no change in refractoriness het-
erogeneity, or conduction velocities, the heterogeneity of con-
duction was substantially increased, and discrete regions of 
slow conduction were observed.21 The heterogeneity in atrial 
conduction index was observed even in a short-duration (two 
weeks) tachypacing-induced HF model.26 A commonly 
observed characteristic in the HF models was enhanced 
fibrous tissue content in the atria,26,27 with reports of both 
extensive interstitial21,25 and diffuse fibrosis.24 The number 
and size of atrial fibrotic patches were also larger in HF sam-
ples compared to the same in controls.24 In addition to fibro-
sis, the HF-induced atrial conduction abnormalities may also 
be partially due to changes in the expression of connexins 
(Cxs); although their density was not altered (mRNA and pro-
tein levels of Cx40 and Cx43), Cx43 was dephosphorylated, 
the ratio of Cx40/Cx43 was increased, and Cx43 was redis-
tributed toward transverse cell boundaries in HF versus con-
trol hearts.26 In a rabbit model with eight weeks of MI, the 
threshold for inducing AF was decreased, and this was shown 
to be associated with increased propensity of APD alternans, 
but no changes in either mean APD or conduction velocity 
were observed.28 In addition to the whole heart, the atrial cel-
lular electrophysiological remodeling in HF has been studied 
extensively, and this has shed light on the underlying ionic 
mechanisms. In the short-term model of ventricular tachypac-
ing in dogs, the atrial cells were hypertrophied, and the APD 
was not changed at slower pacing frequencies but increased in 
duration at rapid pacing frequencies.29 The densities of ICaL, 
Ito1, and the slow delayed rectifier K+ current IKs were reduced 
in HF samples compared to those in controls, but there was no 
change in their voltage dependencies or kinetics.29 The densi-
ties of the K+ currents IK1, IKur, IKr, and the T-type Ca2+ cur-
rent ICaT were not altered, but that of the electrogenic Na+–Ca2+ 
exchanger, INCX, was increased.29 In contrast, in the long-term 
tachypaced canine model of ventricular HF (four months of 
tachypacing), the APD50 and APD90 were significantly short-
ened in atrial isolated cells; this corresponded with a substan-
tially shortened atrial ERP, as measured in vivo.27 Such atrial 
APD shortening resulting from long-term congestive HF was 
confirmed in a subsequent study.30 The ionic changes reported 
included increased Ito1 and decreased IK1, IKur, and IKs.27 Upon 
studying ICaL under action potential clamp conditions, the HF 
atrial action potential reduced the integral of ICaL in control 
healthy cells, with a larger reduction in myocytes from HF 
dogs.27 These data point toward a complex electrical pheno-
type and underlying ionic mechanism changes in the atrium 
in the presence of HF, depending upon the severity of the con-
dition (short-term versus long-term ventricular pacing),31 and, 
in part, mirror the complex and varied phenotypes seen in 
patients with ventricular dysfunction. Besides sarcolemmal 
ion channels, significant dysregulation in atrial intracellular 
Ca2+ ([Ca2+]i) homeostasis and its regulatory components/ 
proteins has been reported in ventricular HF models.28,32–34 
After two weeks of ventricular pacing in canines, Yeh et al 
found that the levels of diastolic Ca2+, [Ca2+]i transient ampli-
tude, and sarcoplasmic reticulum (SR) load were increased, 
and that the enhanced SR load was also associated with spon-
taneous Ca2+ release events.32 The greater SR load was partly 
attributable to a prolonged APD, as well as an increased calm-
odulin-dependent protein kinase II phosphorylation of phos-
pholamban, which potentially reduced the inhibition of SR 
uptake; however, the phosphorylation of SR release channels 
(ryanodine type-2, RyR2) was not affected, but the total RyR2 
and calsequestrin levels were reduced.32 In contrast to these 
findings, in the ovine model of tachypacing-induced HF 
(mean period of tachypacing: ∼33 days), the [Ca2+]i transient 
amplitude and the density of ICaL were both reduced, the atrial 
SR content was increased, and the [Ca2+]i amplitude was simi-
lar in controls and HF during β-adrenergic stimulation.34 In 
the rabbit MI model (eight weeks of infarction), under 
β-adrenergic stimulation, the [Ca2+]i transient amplitude, and 
the density of ICaL were both decreased in MI compared to 
controls, and the frequency of spontaneous depolarizations 
was higher in MI.28 A decrease in the atrial [Ca2+]i transient 
amplitude and SR Ca2+ content was also reported following 
four weeks of MI in rats.35 In both sheep HF33 and rabbit MI 
models,28 there was a marked decrease in the density and net-
work of the transverse T-tubules, and these structural and 
functional changes may partially underlie the focal nature of 
activation of the atrial arrhythmias seen in HF.6,23 Recent 
studies have also begun to investigate the properties and pro-
liferation of fibroblasts in mediating enhanced atrial fibrosis in 
HF.5 In the dog HF model, various signaling pathways that 
underlie apoptosis followed by atrial interstitial fibrosis have 
been identified, which include increased phosphorylation of 
p38 mitogen-activated protein kinases, JNK, and ERK, which 
were preceded by increases in tissue levels of angiotensin II.36 
Different ion channels have been identified to exist in atrial 
fibroblasts, and two K+ channels, namely, the tetraethylam-
monium-sensitive K+ current and Ba2+-sensitive inward recti-
fier K+ current, have been shown to affect fibroblast proliferation 
in the dog HF model.37,38 The voltage-dependent K+ currents 
(conducted through Kv1.5 and Kv4.3 channels) were found to 
be downregulated in HF, and suppressing these currents 
enhanced fibroblast proliferation, suggesting that they may 
play an important role in mediating fibrosis.37 In addition, the 
density of the IK1 current (as well as its mRNA/protein levels) 
was found to be enhanced in atrial fibroblasts isolated from 
Pandit and Workman
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HF dogs, compared to that in healthy controls.38 Overexpression 
of atrial fibroblast IK1 current by lentivirus led to hyperpolar-
ization of Vrest, increased store-operated Ca2+ entry, and fibro-
blast proliferation, and it was suggested that microRNA-26a 
might play a regulatory role.38 A similar role for regulation of 
atrial fibrosis was suggested for microRNA-29, which has 
been shown to be downregulated in the dog HF model and to 
regulate the expression of extracellular matrix proteins such as 
collagen and fibrillin.39 Recent computational studies have 
also investigated the putative bases of fibroblast effects on 
atrial electrophysiology, mainly occurring as a result of cou-
pling between myocytes and atrial fibroblasts.40,41 Simulations 
indicate that such coupling can modulate Vrest and repolariza-
tion, predisposing the atrium to arrhythmogenesis.40,41 How-
ever, direct experimental evidence of such coupling in the 
atrium (or the heart) is still not available. In addition to cou-
pling, fibroblasts/myofibroblasts can influence atrial ion chan-
nels and excitability through secretion of factors such as 
transforming growth factor (TGF)-β1 and platelet-derived 
growth factor and also by direct physical contact that can lead 
to dedifferentiation.42 Another component that may play a 
role in affecting the electrophysiology and inducing AT/AF, 
apart from ionic and structural remodeling, in HF is the 
remodeling of the autonomic nervous system.43 Ogawa et al 
examined nerve activity in the dog model of HF and observed 
that both the left stellate ganglion nerve activity (SGNA) and 
vagal nerve activity (VNA) were increased in HF compared to 
those in controls, and that episodes of paroxysmal AT in a 
majority of cases were induced by simultaneous increases in 
both SGNA and VNA, followed by vagal withdrawal.44 How-
ever, the precise ionic/molecular mechanisms remain to be 
determined. In other studies of atrial autonomic remodeling, 
chronic ventricular tachypacing in pigs was shown to decrease 
atrial beta-1-adrenoceptor expression,45 and chronic MI in 
dogs caused heterogeneous sympathetic nerve sprouting in the 
atrium, accompanied by increased susceptibility to atrial alter-
nans and AF.46 Lastly, the ionic mechanisms underlying how 
inflammation or oxidative stress modulates the atrial 
electrophysiological remodeling occurring in the context of 
HF remain incompletely understood (but also see later in 
the next section).
Therapy for AF in HF
Currently, the main therapy for AF can be broadly classified 
as rate or rhythm control,1 and we will focus on the latter 
aspect in this review. Rhythm control strategies for maintain-
ing sinus rhythm consist of either catheter ablation or the use 
of antiarrhythmic drugs.47 The main antiarrhythmic drugs 
used in HF patients include amiodarone and dofetilide.1,47 
Although the multiple ion channel blocker amiodarone (eg, 
INa, IKr, IKur, Ito1, ICaL, IKs, IKAch, and β-receptors) is the most 
effective available antiarrhythmic, it may be associated with 
significant cardiac adverse consequences (bradycardia, QT 
interval prolongation) and noncardiac toxicities including pul-
monary, thyroid, and liver toxicities.1 Dofetilide, a selective 
blocker of IKr, may increase the risk of QT interval prolon-
gation and torsade de pointes, and inpatient electrocardio-
graphic monitoring is necessary for its use.1 Recent clinical 
trials show that catheter ablation has more success in achiev-
ing freedom from AF, compared to amiodarone, in patients 
with congestive HF.48 However, antiarrhythmic drugs con-
stitute the mainstay of treatment in AF,49 and therefore more 
efforts are needed to develop newer drugs, especially as recent 
efforts to use improved variants of amiodarone (dronaderone) 
proved contraindicatory because of increased mortality, par-
ticularly in HF patients.50 Efforts to develop newer therapies 
have also been explored in experimental animal models of 
HF. The renin–angiotensin–aldosterone system is known to 
be activated in HF,51 and Shroff et al explored whether selec-
tive aldosterone blockade could prevent atrial arrhythmias 
in HF.52 Their study in a dog model of HF found that epler-
enone treatment significantly suppressed atrial arrhythmia 
inducibility, prolonged atrial ERP, but did not affect atrial 
dilatation.52 Because oxidative stress and inflammation may 
also be involved in HF-related atrial remodeling, Shiroshita- 
Takeshita et al investigated the effects of simvastatin on the 
AF substrate in a dog HF model.53 Their results showed 
that simvastatin attenuated atrial conduction abnormalities, 
decreased fibrosis, and suppressed fibroblast proliferation, 
which led to a reduced duration of induced AF episodes.53 
The antifibrotic drug pirfenidone significantly attenuated 
arrhythmogenic atrial remodeling and AF induction in HF 
dogs, in part by reducing TGF-β1 expression (which is pro-
fibrotic).54 In addition to these upstream therapy approaches, 
gap junctions have also been targeted, with mixed results. 
The gap junction modifier rotigaptide (ZP123) did not 
affect inducibility of AF in a dog HF model.55,56 In contrast, 
a novel agent F-16915 significantly reduced the duration of 
AF inducibility in dog HF models, which was partly attrib-
uted to dephosphorylation of Cxs.56 Finally, recent studies 
indicate that ranolazine suppressed the peak atrial INa in HF 
dogs and promoted postrepolarization refractoriness; it was 
thus able to either suppress induction of AF (70% of cases) 
or reduce AF frequency and duration.57 These data sug-
gest ranolazine as a new possible alternative antiarrhythmic 
drug to prevent the recurrence of AF in HF patients. How-
ever, all these drugs/their derivatives need to undergo com-
prehensive clinical trials and tests, before their efficacy is 
reliably proven. Autonomic nerve remodeling also poten-
tially plays a role in initiating AF in HF, and emerging ther-
apies include ablation of ganglionated plexi, or even renal 
sympathetic denervation.43
Future Studies
There is a need to improve mechanistic insights into the 
pathophysiology of atrial remodeling occurring in HF. 
Identifying novel time-dependent signaling pathways that 
underlie electrostructural remodeling by means of proteomics 
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and metabolomics analyses58 will help identify novel therapeutic 
targets, including reactive oxygen species that are now thought 
to play an important role in the progression of AF toward its 
permanent form.59 The pathophysiology underlying HF or con-
comitant comorbidities, such as hypertension, obesity, diabetes, 
sleep apnea, chronic kidney disease, or a combination thereof, 
will also be important in determining patient- or disease-spe-
cific therapy.60 In addition to traditional ionic and upstream 
targets, recent studies indicate an important regulatory role for 
microRNAs and noncoding long RNAs in the pathogenesis of 
HF61,62; it remains to be determined whether these new targets 
can also help ameliorate the arrhythmogenic atrial electrophysi-
ological substrate associated with HF and prevent initiation 
and/or recurrence of AF.
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